Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

3-MeO-PCMo

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
3-MeO-PCMo
Legal status
Legal status
Identifiers
  • 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC17H25NO2
Molar mass275.392 g·mol−1
3D model (JSmol)
  • COC1=CC(C2(N3CCOCC3)CCCCC2)=CC=C1
  • InChI=1S/C17H25NO2/c1-19-16-7-5-6-15(14-16)17(8-3-2-4-9-17)18-10-12-20-13-11-18/h5-7,14H,2-4,8-13H2,1H3
  • Key:BOGOEDFWPOXWQE-UHFFFAOYSA-N

3-MeO-PCMo is adissociativeanesthetic drug which is similar in structure tophencyclidine[1][2] and been sold online as adesigner drug.[3][4] The inhibitory effect of 3-MeO-PCMo on the reduction in the density of thedrebrin clusters byNMDAR stimulation withglutamic acid is lower than that of PCP or 3-MeO-PCP, withhalf maximal inhibitory concentration (IC50) values of 26.67 μM (3-MeO-PCMo), 2.02 μM (PCP) and 1.51 μM (3-MeO-PCP).[5]

See also

[edit]

References

[edit]
  1. ^Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (April 2011). "New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats".Pharmacology, Biochemistry, and Behavior.98 (2):227–33.doi:10.1016/j.pbb.2010.12.019.PMID 21215770.S2CID 24650035.
  2. ^Abiero A, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, et al. (March 2020). "4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels".Psychopharmacology.237 (3):757–772.doi:10.1007/s00213-019-05412-y.PMID 31828394.S2CID 209169410.
  3. ^Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, et al. (February 2018). "Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues".Drug Testing and Analysis.10 (2):272–283.doi:10.1002/dta.2213.PMID 28513099.
  4. ^"3-MeO-PCMo". New Synthetic Drugs Database. Archived fromthe original on 2016-07-03. Retrieved2016-02-09.
  5. ^Mitsuoka T, Hanamura K, Koganezawa N, Kikura-Hanajiri R, Sekino Y, Shirao T (September–October 2019)."Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay".Journal of Pharmacological and Toxicological Methods.99 106583.doi:10.1016/j.vascn.2019.106583.PMID 31082488.
GABAA
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Imidazoles
Monoureides
Neurosteroids
Nonbenzodiazepines
Phenols
Piperidinediones
Quinazolinones
Others
GABAB
H1
Antihistamines
Antidepressants
Antipsychotics
α2-Adrenergic
5-HT2A
Antidepressants
Antipsychotics
Others
Melatonin
Orexin
α2δVDCC
Others
Psychedelics
(5-HT2AR agonists)
  • For a full list of serotonergic psychedelics, see the navboxhere and the listhere instead.
Dissociatives
(NMDARantagonists)
Arylcyclo‐
hexylamines
Adamantanes
Diarylethylamines
Morphinans
Others
Deliriants
(mAChRantagonists)
Cannabinoids
(CB1R agonists)
Natural
Synthetic
AM-x
CPx
HU-x
JWH-x
Misc.
  •  For a full list of cannabinoids, see the navboxhere and the listhere instead.
κORagonists
GABAARagonists
Inhalants
(mixedMoATooltip mechanism of action)
Others
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
KARTooltip Kainate receptor
NMDARTooltip N-Methyl-D-aspartate receptor


Stub icon

Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=3-MeO-PCMo&oldid=1310618704"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp